Individual dosing may vary based on medical history, how you tolerate the medication, and your clinical response.
Research indicates that restoring NAD+ can enhance synaptic transmission and overall cognitive performance in preclinical settings
Your body is not betraying you it is responding to years of adaptation, stress, and metabolic defense
This can help you feel fuller for longer
Beyond weight reduction, the same trial reported several additional metabolic outcomes as secondary or exploratory endpoints: Improved glycaemic control reductions in HbA1c levels were observed in participants with type 2 diabetes in a separate Phase 2 cohort [3] [4] Reduced waist circumference suggesting a decrease in visceral (abdominal) fat, which is associated with cardiovascular risk Improvements in lipid profiles including reductions in triglycerides Potential signal for benefit in metabolic-associated steatotic liver disease (MASLD) based on the glucagon receptor's proposed role in hepatic fat metabolism
Early data showed promising efficacy in non-diabetic obese patients comparable to Lillys Orforglipron with a downward trend in weight loss, although the effect size was less than that of Orforglipron in diabetes subgroup